KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Current Deferred Revenue (2016 - 2017)

Vertex Pharmaceuticals (VRTX) has 9 years of Current Deferred Revenue data on record, last reported at $5.2 million in Q4 2017.

  • For Q4 2017, Current Deferred Revenue fell 13.92% year-over-year to $5.2 million; the TTM value through Dec 2017 reached $5.2 million, down 13.92%, while the annual FY2017 figure was $5.2 million, 13.92% down from the prior year.
  • Current Deferred Revenue reached $5.2 million in Q4 2017 per VRTX's latest filing, down from $13.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $35.5 million in Q1 2013 and bottomed at $5.2 million in Q4 2017.
  • Average Current Deferred Revenue over 5 years is $17.5 million, with a median of $15.4 million recorded in 2015.
  • Peak YoY movement for Current Deferred Revenue: tumbled 63.15% in 2016, then skyrocketed 40.62% in 2017.
  • A 5-year view of Current Deferred Revenue shows it stood at $21.5 million in 2013, then dropped by 18.79% to $17.5 million in 2014, then fell by 6.71% to $16.3 million in 2015, then crashed by 63.15% to $6.0 million in 2016, then decreased by 13.92% to $5.2 million in 2017.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $5.2 million in Q4 2017, $13.0 million in Q3 2017, and $7.3 million in Q2 2017.